Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC48H60N8O6 |
InChIKeyKBASXKZKMMUHSI-XSFVSMFZSA-N |
CAS Registry3023809-62-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 01 Nov 2022 | |
Neoplasms | Preclinical | China | 01 Nov 2022 |